Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Signs Contract with Blue Shield of California

NEW YORK (GenomeWeb News) – Agendia today said that it has signed a contract with Blue Shield of California, making it an in-network provider.

The deal, Agendia said, opens the way for other Blue Cross affiliates nationwide to cover Agendia's tests including its MammaPrint. Other payors, including Medicare, Humana, and United Healthcare, also have coverage policies for MammaPrint, and the company has contracts with Palmetto, Humana, Coventry and other national preferred provider organization plans.

MammaPrint, Agendia's lead product, is a gene expression signature assay for determining which patients with breast cancer may be at risk of metastases. The test can help guide treatment decisions.

The Dutch molecular diagnostics firm filed for an initial public offering in Europe in June but shelved it two weeks later citing adverse market conditions. Most recently David Macdonald replaced Bernhard Sixt as Agendia's CEO.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.